Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
1(100.0%)
1Total
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT04528940Unknown

Tumor Grade Determines PD-1/PDL-1 Expression

Role: lead

NCT04516083Unknown

Lynch Syndrome Can be Diagnosed Just From Somatic Mismatch Repair Mutation

Role: lead

NCT03960970Phase 2Unknown

Two-drug Antibiotic Prophylaxis in Scheduled Cesarean Deliveries

Role: lead

All 3 trials loaded